ICD-10 Coding for Supratherapeutic INR(D68.3, D68.32, D68.32B)
Comprehensive guide on ICD-10 coding for supratherapeutic INR, including documentation requirements, coding pitfalls, and clinical scenarios.
Complete code families applicable to Supratherapeutic INR
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| D68.32 | Hemorrhagic disorder due to intrinsic circulating anticoagulants | Use when there is bleeding associated with supratherapeutic INR due to anticoagulants. |
|
| R79.83 | Abnormal coagulation profile | Use when INR is elevated without bleeding. |
|
| Z92.1 | Personal history of long-term (current) use of anticoagulants | Use when there is a documented history of INR monitoring. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutSupratherapeutic INR
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Supratherapeutic INR.
Omitting causal agent in documentation
Impact
Clinical: May lead to inappropriate treatment adjustments., Regulatory: Non-compliance with coding standards., Financial: Potential claim denials.
Mitigation
Always document the cause of INR elevation.
Coding both Z92.1 and R79.83 together
Impact
Reimbursement: Incorrect coding may lead to denied claims., Compliance: Violates coding guidelines for exclusivity., Data Quality: Leads to inaccurate patient records.
Mitigation
Use R79.83 alone unless INR monitoring is explicitly documented.
Incorrect code combinations
Impact
Using mutually exclusive codes together.
Mitigation
Educate coders on exclusivity rules and proper documentation.